Antineoplastics: Lack of efficacy: 3 case reports.

Despite receiving crizotinib therapy for 7 months, progression of the metastatic NSCLC along with brain metastases was observed indicating lack of efficacy. Despite receiving pemetrexed, docetaxel, ramucirumab, unspecified platinum complexes and selpercatinib therapy, progression of the metastatic NSCLC was observed indicating lack of efficacy. Therefore, she started receiving cyclical treatment with pemetrexed, docetaxel, ramucirumab and unspecified platinum complexes [platinum] doublet therapy. [Extracted from the article]